Is brachytherapy a viable treatment option for muscle-invasive bladder cancer?
-
1
Department of Translational Oncology and Urology Research, Faculty of Life Sciences & Medicine, King's College London, United Kingdom
-
2
City University of London, United Kingdom
-
3
Guy's and St Thomas' NHS Foundation Trust, United Kingdom
Purpose: Muscle-invasive bladder cancer (MIBC) is an aggressive disease with a high mortality rate. Treatment typically involves a cystectomy which is an undesirable option for most patients. Objectives: To evaluate the clinical effectiveness of brachytherapy for solitary urinary bladder tumours in terms of survival. Methods: A systematic review was conducted using the preferred reporting items of systematic reviews and meta-analysis (PRISMA) guidelines with defined search terms: an online search was performed using the PubMed database with the terms brachytherapy AND urinary bladder cancer AND survival. Three individual searches were performed using MeSH and title/abstract searches. The builder option was used to combine the three initial searches which resulted in 80 articles. Results: 21 studies were included in the final analysis. Ten separate endpoints were reported within the articles, 17 of the 21 articles reported overall survival at 5 years, with a combined number of 2889 patients at risk and 1775 alive after 5 years (61.4%) Conclusion: Brachytherapy for MIBC is an alternative (and organ preserving option) for solidarity (<5cm) tumours when combined with a short course of external beam radiotherapy.
Keywords:
Brachytherapy,
muscle invasive bladder cancer,
Survival,
Internal radiation,
Urinary bladdder
Conference:
Bladder Cancer Translational Research Meeting, London, United Kingdom, 29 Mar - 29 Mar, 2019.
Presentation Type:
Poster
Topic:
Development of personalised treatment
Citation:
Mannion
L,
Van Hemelrijck
M and
Hughes
S
(2019). Is brachytherapy a viable treatment option for muscle-invasive bladder cancer?.
Front. Oncol.
Conference Abstract:
Bladder Cancer Translational Research Meeting.
doi: 10.3389/conf.fonc.2019.01.00011
Copyright:
The abstracts in this collection have not been subject to any Frontiers peer review or checks, and are not endorsed by Frontiers.
They are made available through the Frontiers publishing platform as a service to conference organizers and presenters.
The copyright in the individual abstracts is owned by the author of each abstract or his/her employer unless otherwise stated.
Each abstract, as well as the collection of abstracts, are published under a Creative Commons CC-BY 4.0 (attribution) licence (https://creativecommons.org/licenses/by/4.0/) and may thus be reproduced, translated, adapted and be the subject of derivative works provided the authors and Frontiers are attributed.
For Frontiers’ terms and conditions please see https://www.frontiersin.org/legal/terms-and-conditions.
Received:
01 Mar 2019;
Published Online:
27 Sep 2019.
*
Correspondence:
Mr. Liam Mannion, Department of Translational Oncology and Urology Research, Faculty of Life Sciences & Medicine, King's College London, London, SE1 1UL, United Kingdom, Liam.mannion@city.ac.uk